Antiviral activity of 5-aminolevulinic acid against variants of severe acute respiratory syndrome coronavirus 2
Abstract Background Genetic variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began to emerge in 2020 and have been spreading globally during the coronavirus disease 2019 (COVID-19) pandemic. Despite the presence of different COVID-19 vaccines, the discovery of effective antiv...
Published in: | Tropical Medicine and Health |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
BMC
2022
|
Subjects: | |
Online Access: | https://doi.org/10.1186/s41182-021-00397-x https://doaj.org/article/99bc2d36cb9e487397801fa7078150e5 |
id |
ftdoajarticles:oai:doaj.org/article:99bc2d36cb9e487397801fa7078150e5 |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:99bc2d36cb9e487397801fa7078150e5 2023-05-15T15:11:29+02:00 Antiviral activity of 5-aminolevulinic acid against variants of severe acute respiratory syndrome coronavirus 2 Mya Myat Ngwe Tun Takaya Sakura Yasuteru Sakurai Yohei Kurosaki Daniel Ken Inaoka Norifumi Shioda Jiro Yasuda Kiyoshi Kita Kouichi Morita 2022-01-01T00:00:00Z https://doi.org/10.1186/s41182-021-00397-x https://doaj.org/article/99bc2d36cb9e487397801fa7078150e5 EN eng BMC https://doi.org/10.1186/s41182-021-00397-x https://doaj.org/toc/1349-4147 doi:10.1186/s41182-021-00397-x 1349-4147 https://doaj.org/article/99bc2d36cb9e487397801fa7078150e5 Tropical Medicine and Health, Vol 50, Iss 1, Pp 1-9 (2022) SARS-CoV-2 variants 5-ALA SFC Anti-viral drug Arctic medicine. Tropical medicine RC955-962 article 2022 ftdoajarticles https://doi.org/10.1186/s41182-021-00397-x 2022-12-30T20:36:36Z Abstract Background Genetic variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began to emerge in 2020 and have been spreading globally during the coronavirus disease 2019 (COVID-19) pandemic. Despite the presence of different COVID-19 vaccines, the discovery of effective antiviral therapeutics for the treatment of patients infected with SARS-CoV-2 are still urgently needed. A natural amino acid, 5-aminolevulinic acid (5-ALA), has exhibited both antiviral and anti-inflammatory activities. In a previous study, we demonstrated an in vitro antiviral effect of 5-ALA against SARS-CoV-2 infection without significant cytotoxicity. In the present study, we sought to investigate whether 5-ALA with or without sodium ferrous citrate (SFC) can inhibit in vitro both the original SARS-CoV-2 Wuhan strain and its variants, including the Alpha, Beta, Gamma and Delta strains. Methods The antiviral activity of ALA with or without SFC was determined in Vero-E6 cell. The virus inhibition was quantified by real time RT-PCR. Results Co-administration of 5-ALA and SFC inhibited the Wuhan, Alpha and Delta variants of SARS-CoV-2 with IC50 values of 235, 173 and 397 µM, respectively, and the Beta and Gamma variants with IC50 values of 1311 and 1516 µM. Conclusion Our study suggests that 5-ALA with SFC warrants accelerated clinical evaluation as an antiviral drug candidate for treating patients infected with SARS-CoV-2 variants. Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic Tropical Medicine and Health 50 1 |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
English |
topic |
SARS-CoV-2 variants 5-ALA SFC Anti-viral drug Arctic medicine. Tropical medicine RC955-962 |
spellingShingle |
SARS-CoV-2 variants 5-ALA SFC Anti-viral drug Arctic medicine. Tropical medicine RC955-962 Mya Myat Ngwe Tun Takaya Sakura Yasuteru Sakurai Yohei Kurosaki Daniel Ken Inaoka Norifumi Shioda Jiro Yasuda Kiyoshi Kita Kouichi Morita Antiviral activity of 5-aminolevulinic acid against variants of severe acute respiratory syndrome coronavirus 2 |
topic_facet |
SARS-CoV-2 variants 5-ALA SFC Anti-viral drug Arctic medicine. Tropical medicine RC955-962 |
description |
Abstract Background Genetic variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began to emerge in 2020 and have been spreading globally during the coronavirus disease 2019 (COVID-19) pandemic. Despite the presence of different COVID-19 vaccines, the discovery of effective antiviral therapeutics for the treatment of patients infected with SARS-CoV-2 are still urgently needed. A natural amino acid, 5-aminolevulinic acid (5-ALA), has exhibited both antiviral and anti-inflammatory activities. In a previous study, we demonstrated an in vitro antiviral effect of 5-ALA against SARS-CoV-2 infection without significant cytotoxicity. In the present study, we sought to investigate whether 5-ALA with or without sodium ferrous citrate (SFC) can inhibit in vitro both the original SARS-CoV-2 Wuhan strain and its variants, including the Alpha, Beta, Gamma and Delta strains. Methods The antiviral activity of ALA with or without SFC was determined in Vero-E6 cell. The virus inhibition was quantified by real time RT-PCR. Results Co-administration of 5-ALA and SFC inhibited the Wuhan, Alpha and Delta variants of SARS-CoV-2 with IC50 values of 235, 173 and 397 µM, respectively, and the Beta and Gamma variants with IC50 values of 1311 and 1516 µM. Conclusion Our study suggests that 5-ALA with SFC warrants accelerated clinical evaluation as an antiviral drug candidate for treating patients infected with SARS-CoV-2 variants. |
format |
Article in Journal/Newspaper |
author |
Mya Myat Ngwe Tun Takaya Sakura Yasuteru Sakurai Yohei Kurosaki Daniel Ken Inaoka Norifumi Shioda Jiro Yasuda Kiyoshi Kita Kouichi Morita |
author_facet |
Mya Myat Ngwe Tun Takaya Sakura Yasuteru Sakurai Yohei Kurosaki Daniel Ken Inaoka Norifumi Shioda Jiro Yasuda Kiyoshi Kita Kouichi Morita |
author_sort |
Mya Myat Ngwe Tun |
title |
Antiviral activity of 5-aminolevulinic acid against variants of severe acute respiratory syndrome coronavirus 2 |
title_short |
Antiviral activity of 5-aminolevulinic acid against variants of severe acute respiratory syndrome coronavirus 2 |
title_full |
Antiviral activity of 5-aminolevulinic acid against variants of severe acute respiratory syndrome coronavirus 2 |
title_fullStr |
Antiviral activity of 5-aminolevulinic acid against variants of severe acute respiratory syndrome coronavirus 2 |
title_full_unstemmed |
Antiviral activity of 5-aminolevulinic acid against variants of severe acute respiratory syndrome coronavirus 2 |
title_sort |
antiviral activity of 5-aminolevulinic acid against variants of severe acute respiratory syndrome coronavirus 2 |
publisher |
BMC |
publishDate |
2022 |
url |
https://doi.org/10.1186/s41182-021-00397-x https://doaj.org/article/99bc2d36cb9e487397801fa7078150e5 |
geographic |
Arctic |
geographic_facet |
Arctic |
genre |
Arctic |
genre_facet |
Arctic |
op_source |
Tropical Medicine and Health, Vol 50, Iss 1, Pp 1-9 (2022) |
op_relation |
https://doi.org/10.1186/s41182-021-00397-x https://doaj.org/toc/1349-4147 doi:10.1186/s41182-021-00397-x 1349-4147 https://doaj.org/article/99bc2d36cb9e487397801fa7078150e5 |
op_doi |
https://doi.org/10.1186/s41182-021-00397-x |
container_title |
Tropical Medicine and Health |
container_volume |
50 |
container_issue |
1 |
_version_ |
1766342332791128064 |